Zymeworks Inc.

Zymeworks is a global biotechnology company that manages a portfolio of licensed healthcare assets and develops new, multifunctional biotherapeutics. These biotherapeutics aim to improve treatment for difficult conditions such as cancer, inflammation, and autoimmune disease. The company's strategy focuses on increasing stockholder value through royalty growth, strategic acquisitions, and internal innovation. This is supported by disciplined capital allocation and a stronger financial foundation from expected milestone payments and royalties from existing commercial partners. Zymeworks discovers or acquires and develops a diversified portfolio of preclinical or clinical healthcare assets. It also evaluates strategic partnership opportunities to transfer certain costs and risks related to clinical development and/or commercialization to partners, securing the right to receive potential future royalty and milestone revenues. The company uses its expertise in protein engineering and drug chemistry to discover and develop next-generation antibody-based therapeutics for significant unmet medical needs, especially in hard-to-treat diseases. Its proprietary structure-guided molecular modeling, combined with internal antibody discovery and generation technologies, supports a fully integrated drug development engine. Zymeworks' pipeline of multifunctional therapeutics is supported by its multispecific antibody therapeutics ("MSATs") and antibody-drug conjugates ("ADCs") technology platforms, which enable the development of novel therapeutics in cancer, inflammation, and autoimmune disease and create opportunities for new partnerships. Partnerships and collaborations are a key part of its strategy, serving as a potential source of funding for ongoing research and development and reducing reliance on internal capital for later-stage clinical development of partnered assets.